Canagliflozin (Invokana®): a First-in-Class Anti-diabetic Drug

  • Sukanta Sen Department of Clinical & Experimental Pharmacology, Calcutta School of Tropical Medicine, Kolkata

Abstract

The US Food and Drug Administration have approved (on March 29, 2013) a novel glucose-lowering agent, canagliflozin (Invokana, Janssen Pharmaceuticals) for the treatment of adults with type 2 diabetes. Canagliflozin is the first in a new class of drug, an oral inhibitor of sodium glucose cotransporter 2 (SGLT2). Inhibition of SGLT2 decreases glucose reabsorption in the renal tubule and increases urinary glucose excretion (UGE), with a consequent lowering of plasma glucose levels as well as weight loss.The profile of effective glucose lowering, weight loss, improved b-cell function, and low risk of hypoglycemia suggest that canagliflozin may be a clinically useful new antihyperglycemic agent.

Downloads

Download data is not yet available.

Author Biography

Sukanta Sen, Department of Clinical & Experimental Pharmacology, Calcutta School of Tropical Medicine, Kolkata

Dr Sukanta Sen MBBS, MD, DNB

Department of Clinical & Experimental Pharmacology, Calcutta School of Tropical Medicine, 108 CR Avenue, Kolkata-700073

Statistics
61 Views | 41 Downloads
How to Cite
Sen, S. (2013). Canagliflozin (Invokana®): a First-in-Class Anti-diabetic Drug. Journal of Drug Delivery and Therapeutics, 3(3), 145-146. https://doi.org/10.22270/jddt.v3i3.490